Short answer
Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on September 17, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Investor presentation furnished under Regulation FD for AQST’s H.C. Wainwright conference meetings.
Aquestive Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor presentation furnished under Regulation FD for AQST’s H.C. Wainwright conference meetings
- Presentation dated September 14, 2026, targeting institutional investors and analysts
- Updates may follow through future 8-K filings, company filings, or other disclosures
- Exhibit 99.2 contains the substantive investor materials and may affect investor expectations
Item 8.01 · Other Events
- Anaphylm NDA resubmitted to FDA for Type I allergic reactions, including anaphylaxis
- Regulatory milestone potentially restarts FDA review toward commercialization
- Press release attached as Exhibit 99.1 for resubmission details
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aquestive Therapeutics, Inc. 8-K filings
Get the next AQST 8-K as it lands
Follow AQST for push alerts, or ask the research agent what this filing means.